Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Analysis of Racial Differences in the Incidence of a Targetable Biomarker, t(11;14), in Patients with Multiple Myeloma

Fang Liu, MD, Jeries Kort, MD, Shashirekha Shetty, PhD, Ravikumar Kyasaram, John Shanahan, Timothy E. O'Brien, MD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-140133

Published: 2020

Journal Articles

Somatic Mutations of the Breast Cancer Amplified Sequence-1 (BCAS1 ), a Novel Leukemogenic Driver in Myelodysplastic Syndromes with Del(20q)

Valeria Visconte, PhD, Ali Tabarroki, MD, John Barnard, Li Zhang, Juraj Bodo, PhD, Reda Mahfouz, MD, Betty K. Hamilton, MD, Mikkael Sekeres, Anjali S. Advani, MD, Matt E. Kalaycio, MD, Yogen Saunthararajah, MD, Velizar Shivarov, MD, PhD, Shashirekha Shetty, PhD, Heesun J. Rogers, MD PhD, Ramon V. Tiu, MD

Blood (2014) 124 (21): 3250.

https://doi.org/10.1182/blood.V124.21.3250.3250

Published: 2014

Journal Articles

Poor Survival Outcomes In Myelodysplastic Syndrome Patients With Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Influenced By SRSF2 Mutations

Jing Ai, MD, PhD, Valeria Visconte, PhD, Ali Tabarroki, MD, Edy Hasrouni, Betty K. Hamilton, MD, Sudipto Mukherjee, MD, PhD, MPH, Matt Kalaycio, MD, Ronald M. Sobecks, MD, Anjali S. Advani, MD, Mikkael A. Sekeres, MD, MS, Shashirekha Shetty, PhD, Ramon V. Tiu, MD

Blood (2013) 122 (21): 2809.

https://doi.org/10.1182/blood.V122.21.2809.2809

Published: 2013

Journal Articles

Combination Of Ibrutinib With ABT-199, a BCL-2 Pathway Inhibitor: Effective Therapeutic Strategy In a Novel Mantle Cell Lymphoma Cell Line Model

Xiaoxian Zhao, PhD, Juraj Bodo, PhD, Danyu Sun, MD, PhD, Jeffrey J. Lin, PhD, Lisa Durkin, Shashirekha Shetty, PhD, Mitchell R. Smith, MD, PhD, Eric D. Hsi, MD

Blood (2013) 122 (21): 645.

https://doi.org/10.1182/blood.V122.21.645.645

Published: 2013

Journal Articles

Molecular Characterization Of Myeloid Neoplasms Harboring Isochromosome 17q Abnormality

Valeria Visconte, PhD, Ali Tabarroki, MD, Li Zhang, Edy Hasrouni, Chris Gerace, Robyn Frum, Anjali S. Advani, MD, Hien K. Duong, MD, Matt Kalaycio, MD, Yogen Saunthararajah, M.D., Mikkael A. Sekeres, MD, MS, Eric D. Hsi, MD, Shashirekha Shetty, PhD, Heesun J. Rogers, MD, PhD, Ramon V. Tiu, MD

Blood (2013) 122 (21): 2596.

https://doi.org/10.1182/blood.V122.21.2596.2596

Published: 2013

NARROW

Analysis of Racial Differences in the Incidence of a Targetable Biomarker, t(11;14), in Patients with Multiple Myeloma

Somatic Mutations of the Breast Cancer Amplified Sequence-1 (BCAS1 ), a Novel Leukemogenic Driver in Myelodysplastic Syndromes with Del(20q)

Poor Survival Outcomes In Myelodysplastic Syndrome Patients With Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Influenced By SRSF2 Mutations

Combination Of Ibrutinib With ABT-199, a BCL-2 Pathway Inhibitor: Effective Therapeutic Strategy In a Novel Mantle Cell Lymphoma Cell Line Model

Molecular Characterization Of Myeloid Neoplasms Harboring Isochromosome 17q Abnormality

Email alerts

ASH Publications

American Society of Hematology

Analysis of Racial Differences in the Incidence of a Targetable Biomarker, t(11;14), in Patients with Multiple Myeloma

Somatic Mutations of the Breast Cancer Amplified Sequence-1 (BCAS1 ), a Novel Leukemogenic Driver in Myelodysplastic Syndromes with Del(20q)

Poor Survival Outcomes In Myelodysplastic Syndrome Patients With Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Influenced By SRSF2 Mutations

Combination Of Ibrutinib With ABT-199, a BCL-2 Pathway Inhibitor: Effective Therapeutic Strategy In a Novel Mantle Cell Lymphoma Cell Line Model

Molecular Characterization Of Myeloid Neoplasms Harboring Isochromosome 17q Abnormality

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only